The Amaxa nucleofector uses a novel non-viral transfection technology to introduce nucleic acids (both DNA and RNA) into stem cells, primary cells, and cell lines that are difficult to transfect.
It employs a non-viral method based on an optimized combination of electrical parameters and cell-type specific solutions.
Both DNA and RNA are efficiently transfected into both the cytoplasm and nucleus of cells. Thus, the Amaxa provides the ability to transfect even non-dividing cells, such as neurons and resting blood cells.
In addition, the transfection efficiency is much higher than traditional methods can achieve. Experiments involving transfection of siRNA or RNAi, transient or stable gene expression, small-scale protein production are all possible.
The Amaxa is compatible with individual cuvettes as well as 96-well trays.
Rates are hourly and are subject to change without further notice.
Valid through July 31, 2019.
|RPI Users||External Nonprofit||External Industry||External Industry Partners|